Skip to main content
Erschienen in: Digestive Diseases and Sciences 11/2018

25.08.2018 | Original Article

Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis: Non-pancolitis Versus Pancolitis

verfasst von: Dong Suk Shin, Jae Hee Cheon, Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim

Erschienen in: Digestive Diseases and Sciences | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Background and Aim

Few studies have compared pancolitis and non-pancolitis E3 in adult patients with ulcerative colitis (UC). This study aimed to evaluate the natural disease courses and factors affecting outcomes between pancolitis and non-pancolitis E3.

Methods

We retrospectively analyzed 117 patients, including 93 with extensive colitis (E3) and 24 with UC confined to the rectum or left-sided colon and appendiceal orifice inflammation at the time of diagnosis, who were regularly followed up for at least 1 year. Patients with E3 were divided into two groups according to the degree of disease extension: pancolitis group (disease extent up to the cecum or proximal ascending colon) and non-pancolitis E3 group (disease extent above the splenic flexure but not up to the proximal ascending colon). Clinical findings at diagnosis; comorbidity; medications; Mayo score; cumulative rates of corticosteroid, immunomodulator, and anti-tumor necrosis factor (anti-TNF) alpha use; relapse; and admission were compared between the pancolitis and non-pancolitis E3 groups.

Results

The median follow-up duration of the 117 patients was 74 (range 15–158) months. Fifty-one patients (43.5%) had pancolitis. The Mayo score at initial diagnosis, cumulative relapse rate, and cumulative admission rate were significantly higher in the pancolitis group than in the non-pancolitis E3 group (P < 0.001, P = 0.023 and P = 0.007, respectively). However, there was no significant difference between the groups in the rates of cumulative immunomodulator and anti-TNF alpha use (P = 0.67 and P = 0.73, respectively).

Conclusions

In patients with extensive UC (E3), pancolitis was associated with higher probabilities of cumulative relapse or admission, indicating poor prognosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725.CrossRef Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725.CrossRef
2.
Zurück zum Zitat Bernstein CN, Ng SC, Lakatos PL, et al. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis. 2013;19:2001–2201.PubMed Bernstein CN, Ng SC, Lakatos PL, et al. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis. 2013;19:2001–2201.PubMed
3.
Zurück zum Zitat Kim B, Park SJ, Hong SP, et al. Proximal disease extension and related predicting factors in ulcerative proctitis. Scand J Gastroenterol. 2014;49:177–183.CrossRef Kim B, Park SJ, Hong SP, et al. Proximal disease extension and related predicting factors in ulcerative proctitis. Scand J Gastroenterol. 2014;49:177–183.CrossRef
4.
Zurück zum Zitat Zhang CK, Hewett J, Hemming J, et al. The influence of depression on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1732–1739.CrossRef Zhang CK, Hewett J, Hemming J, et al. The influence of depression on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1732–1739.CrossRef
5.
Zurück zum Zitat Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–429.CrossRef Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–429.CrossRef
6.
Zurück zum Zitat Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.CrossRef Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.CrossRef
7.
Zurück zum Zitat Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19:789–799.CrossRef Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19:789–799.CrossRef
8.
Zurück zum Zitat Katz J. The course of inflammatory bowel disease. Med Clin N Am. 1994;78:1275–1280.CrossRef Katz J. The course of inflammatory bowel disease. Med Clin N Am. 1994;78:1275–1280.CrossRef
9.
Zurück zum Zitat Sahami S, Konte K, Buskens CJ, et al. Risk factors for proximal disease extension and colectomy in left-sided ulcerative colitis. United Eur Gastroenterol J. 2017;5:554–562.CrossRef Sahami S, Konte K, Buskens CJ, et al. Risk factors for proximal disease extension and colectomy in left-sided ulcerative colitis. United Eur Gastroenterol J. 2017;5:554–562.CrossRef
10.
Zurück zum Zitat Eszter Muller K, Laszlo Lakatos P, Papp M, et al. Incidence and paris classification of pediatric inflammatory bowel disease. Gastroenterol Res Pract. 2014;2014:904307.CrossRef Eszter Muller K, Laszlo Lakatos P, Papp M, et al. Incidence and paris classification of pediatric inflammatory bowel disease. Gastroenterol Res Pract. 2014;2014:904307.CrossRef
11.
Zurück zum Zitat Muller KE, Lakatos PL, Arato A, et al. Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;57:576–582.CrossRef Muller KE, Lakatos PL, Arato A, et al. Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;57:576–582.CrossRef
12.
Zurück zum Zitat Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203–1209.CrossRef Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203–1209.CrossRef
13.
Zurück zum Zitat Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.CrossRef Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.CrossRef
14.
Zurück zum Zitat Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.CrossRef Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.CrossRef
15.
Zurück zum Zitat Turner D, Seow CH, Greenberg GR, et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1081–1088.CrossRef Turner D, Seow CH, Greenberg GR, et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1081–1088.CrossRef
16.
Zurück zum Zitat Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.CrossRef Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.CrossRef
17.
Zurück zum Zitat O’Morain C, Tobin A, Leen E, et al. Criteria of case definition in Crohn’s disease and ulcerative colitis. Scand J Gastroenterol Suppl. 1989;170:7–11. discussion 16–19.CrossRef O’Morain C, Tobin A, Leen E, et al. Criteria of case definition in Crohn’s disease and ulcerative colitis. Scand J Gastroenterol Suppl. 1989;170:7–11. discussion 16–19.CrossRef
19.
Zurück zum Zitat Prantera C, Davoli M, Lorenzetti R, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol. 1988;10:41–45.CrossRef Prantera C, Davoli M, Lorenzetti R, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol. 1988;10:41–45.CrossRef
22.
Zurück zum Zitat Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). Scand J Gastroenterol. 2009;44:431–440.CrossRef Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). Scand J Gastroenterol. 2009;44:431–440.CrossRef
23.
Zurück zum Zitat Abdalla M, Landerholm K, Andersson P, et al. Risk of rectal cancer after colectomy for patients with ulcerative colitis: a national cohort study. Clin Gastroenterol Hepatol. 2017;15:1055.e1052–1060.e1052.CrossRef Abdalla M, Landerholm K, Andersson P, et al. Risk of rectal cancer after colectomy for patients with ulcerative colitis: a national cohort study. Clin Gastroenterol Hepatol. 2017;15:1055.e1052–1060.e1052.CrossRef
24.
Zurück zum Zitat Myrelid P, Landerholm K, Nordenvall C, et al. Appendectomy and the risk of colectomy in ulcerative colitis: a national cohort study. Am J Gastroenterol. 2017;112:1311–1319.CrossRef Myrelid P, Landerholm K, Nordenvall C, et al. Appendectomy and the risk of colectomy in ulcerative colitis: a national cohort study. Am J Gastroenterol. 2017;112:1311–1319.CrossRef
25.
Zurück zum Zitat Fukuda T, Naganuma M, Sugimoto S, et al. The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: a report from the IBD registry. PLoS ONE. 2017;12:e0187737.CrossRef Fukuda T, Naganuma M, Sugimoto S, et al. The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: a report from the IBD registry. PLoS ONE. 2017;12:e0187737.CrossRef
26.
Zurück zum Zitat Park BJ, Lee KJ, Hwang JC, et al. Relapse rates of ulcerative colitis in remission and factors related to relapse. Korean J Gastroenterol. 2008;52:21–26.PubMed Park BJ, Lee KJ, Hwang JC, et al. Relapse rates of ulcerative colitis in remission and factors related to relapse. Korean J Gastroenterol. 2008;52:21–26.PubMed
27.
Zurück zum Zitat Mudireddy P, Scott F, Feathers A, et al. Inflammatory bowel disease: predictors and causes of early and late hospital readmissions. Inflamm Bowel Dis. 2017;23:1832–1839.CrossRef Mudireddy P, Scott F, Feathers A, et al. Inflammatory bowel disease: predictors and causes of early and late hospital readmissions. Inflamm Bowel Dis. 2017;23:1832–1839.CrossRef
Metadaten
Titel
Extensive Disease Subtypes in Adult Patients with Ulcerative Colitis: Non-pancolitis Versus Pancolitis
verfasst von
Dong Suk Shin
Jae Hee Cheon
Yong Eun Park
Yehyun Park
Soo Jung Park
Tae Il Kim
Won Ho Kim
Publikationsdatum
25.08.2018
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 11/2018
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5218-x

Weitere Artikel der Ausgabe 11/2018

Digestive Diseases and Sciences 11/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.